

Prostate Cancer Medicine-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data

<https://marketpublishers.com/r/P6ED95439033EN.html>

Date: December 2021

Pages: 133

Price: US\$ 3,680.00 (Single User License)

ID: P6ED95439033EN

Abstracts

Report Summary

Prostate Cancer Medicine-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data offers a comprehensive analysis on Prostate Cancer Medicine industry, standing on the readers' perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:

Worldwide and Top 20 Countries Market Size of Prostate Cancer Medicine 2016-2021, and development forecast 2022-2026

Main manufacturers/suppliers of Prostate Cancer Medicine worldwide and market share by regions, with company and product introduction, position in the Prostate Cancer Medicine market

Market status and development trend of Prostate Cancer Medicine by types and applications

Cost and profit status of Prostate Cancer Medicine, and marketing status

Market growth drivers and challenges Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Ammonium Prostate Cancer Medicine market in 2020. COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all

indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future. This report also analyses the impact of Coronavirus COVID-19 on the Prostate Cancer Medicine industry.

The report segments the global Prostate Cancer Medicine market as:

Global Prostate Cancer Medicine Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2016-2026):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa

Global Prostate Cancer Medicine Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2016-2026):
LHRH Antagonists
LHRH Analogs
Antiandrogens
Pipeline Drugs for Hormonal Therapy

Global Prostate Cancer Medicine Market: Application Segment Analysis (Consumption Volume and Market Share 2016-2026; Downstream Customers and Market Analysis)
Age Below 55
Age 55-75
Age Above 75

Global Prostate Cancer Medicine Market: Manufacturers Segment Analysis (Company and Product introduction, Prostate Cancer Medicine Sales Volume, Revenue, Price and Gross Margin):
AstraZeneca plc
Active Biotech
Bristol Myers-Squibb
Teva Pharmaceuticals Industries Ltd.
Johnson & Johnson
Pfizer Inc.
Bayer AG

Abbott Laboratories
Astellas Pharma Inc.
Roche Holding AG

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

Contents

CHAPTER 1 OVERVIEW OF PROSTATE CANCER MEDICINE

- 1.1 Definition of Prostate Cancer Medicine in This Report
- 1.2 Commercial Types of Prostate Cancer Medicine
 - 1.2.1 LHRH Antagonists
 - 1.2.2 LHRH Analogs
 - 1.2.3 Antiandrogens
 - 1.2.4 Pipeline Drugs for Hormonal Therapy
- 1.3 Downstream Application of Prostate Cancer Medicine
 - 1.3.1 Age Below
 - 1.3.2 Age 55-75
 - 1.3.3 Age Above
- 1.4 Development History of Prostate Cancer Medicine
- 1.5 Market Status and Trend of Prostate Cancer Medicine 2016-2026
 - 1.5.1 Global Prostate Cancer Medicine Market Status and Trend 2016-2026
 - 1.5.2 Regional Prostate Cancer Medicine Market Status and Trend 2016-2026

CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS

- 2.1 Market Development of Prostate Cancer Medicine 2016-2021
- 2.2 Sales Market of Prostate Cancer Medicine by Regions
 - 2.2.1 Sales Volume of Prostate Cancer Medicine by Regions
 - 2.2.2 Sales Value of Prostate Cancer Medicine by Regions
- 2.3 Production Market of Prostate Cancer Medicine by Regions
- 2.4 Global Market Forecast of Prostate Cancer Medicine 2022-2026
 - 2.4.1 Global Market Forecast of Prostate Cancer Medicine 2022-2026
 - 2.4.2 Market Forecast of Prostate Cancer Medicine by Regions 2022-2026

CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES

- 3.1 Sales Volume of Prostate Cancer Medicine by Types
- 3.2 Sales Value of Prostate Cancer Medicine by Types
- 3.3 Market Forecast of Prostate Cancer Medicine by Types

CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY

- 4.1 Global Sales Volume of Prostate Cancer Medicine by Downstream Industry
- 4.2 Global Market Forecast of Prostate Cancer Medicine by Downstream Industry

CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 5.1 North America Prostate Cancer Medicine Market Status by Countries
 - 5.1.1 North America Prostate Cancer Medicine Sales by Countries (2016-2021)
 - 5.1.2 North America Prostate Cancer Medicine Revenue by Countries (2016-2021)
 - 5.1.3 United States Prostate Cancer Medicine Market Status (2016-2021)
 - 5.1.4 Canada Prostate Cancer Medicine Market Status (2016-2021)
 - 5.1.5 Mexico Prostate Cancer Medicine Market Status (2016-2021)
- 5.2 North America Prostate Cancer Medicine Market Status by Manufacturers
- 5.3 North America Prostate Cancer Medicine Market Status by Type (2016-2021)
 - 5.3.1 North America Prostate Cancer Medicine Sales by Type (2016-2021)
 - 5.3.2 North America Prostate Cancer Medicine Revenue by Type (2016-2021)
- 5.4 North America Prostate Cancer Medicine Market Status by Downstream Industry (2016-2021)

CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 6.1 Europe Prostate Cancer Medicine Market Status by Countries
 - 6.1.1 Europe Prostate Cancer Medicine Sales by Countries (2016-2021)
 - 6.1.2 Europe Prostate Cancer Medicine Revenue by Countries (2016-2021)
 - 6.1.3 Germany Prostate Cancer Medicine Market Status (2016-2021)
 - 6.1.4 UK Prostate Cancer Medicine Market Status (2016-2021)
 - 6.1.5 France Prostate Cancer Medicine Market Status (2016-2021)
 - 6.1.6 Italy Prostate Cancer Medicine Market Status (2016-2021)
 - 6.1.7 Russia Prostate Cancer Medicine Market Status (2016-2021)
 - 6.1.8 Spain Prostate Cancer Medicine Market Status (2016-2021)
 - 6.1.9 Benelux Prostate Cancer Medicine Market Status (2016-2021)
- 6.2 Europe Prostate Cancer Medicine Market Status by Manufacturers
- 6.3 Europe Prostate Cancer Medicine Market Status by Type (2016-2021)
 - 6.3.1 Europe Prostate Cancer Medicine Sales by Type (2016-2021)
 - 6.3.2 Europe Prostate Cancer Medicine Revenue by Type (2016-2021)
- 6.4 Europe Prostate Cancer Medicine Market Status by Downstream Industry (2016-2021)

CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 7.1 Asia Pacific Prostate Cancer Medicine Market Status by Countries
 - 7.1.1 Asia Pacific Prostate Cancer Medicine Sales by Countries (2016-2021)
 - 7.1.2 Asia Pacific Prostate Cancer Medicine Revenue by Countries (2016-2021)
 - 7.1.3 China Prostate Cancer Medicine Market Status (2016-2021)
 - 7.1.4 Japan Prostate Cancer Medicine Market Status (2016-2021)
 - 7.1.5 India Prostate Cancer Medicine Market Status (2016-2021)
 - 7.1.6 Southeast Asia Prostate Cancer Medicine Market Status (2016-2021)
 - 7.1.7 Australia Prostate Cancer Medicine Market Status (2016-2021)
- 7.2 Asia Pacific Prostate Cancer Medicine Market Status by Manufacturers
- 7.3 Asia Pacific Prostate Cancer Medicine Market Status by Type (2016-2021)
 - 7.3.1 Asia Pacific Prostate Cancer Medicine Sales by Type (2016-2021)
 - 7.3.2 Asia Pacific Prostate Cancer Medicine Revenue by Type (2016-2021)
- 7.4 Asia Pacific Prostate Cancer Medicine Market Status by Downstream Industry (2016-2021)

CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 8.1 Latin America Prostate Cancer Medicine Market Status by Countries
 - 8.1.1 Latin America Prostate Cancer Medicine Sales by Countries (2016-2021)
 - 8.1.2 Latin America Prostate Cancer Medicine Revenue by Countries (2016-2021)
 - 8.1.3 Brazil Prostate Cancer Medicine Market Status (2016-2021)
 - 8.1.4 Argentina Prostate Cancer Medicine Market Status (2016-2021)
 - 8.1.5 Colombia Prostate Cancer Medicine Market Status (2016-2021)
- 8.2 Latin America Prostate Cancer Medicine Market Status by Manufacturers
- 8.3 Latin America Prostate Cancer Medicine Market Status by Type (2016-2021)
 - 8.3.1 Latin America Prostate Cancer Medicine Sales by Type (2016-2021)
 - 8.3.2 Latin America Prostate Cancer Medicine Revenue by Type (2016-2021)
- 8.4 Latin America Prostate Cancer Medicine Market Status by Downstream Industry (2016-2021)

CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY

- 9.1 Middle East and Africa Prostate Cancer Medicine Market Status by Countries
 - 9.1.1 Middle East and Africa Prostate Cancer Medicine Sales by Countries

(2016-2021)

9.1.2 Middle East and Africa Prostate Cancer Medicine Revenue by Countries

(2016-2021)

9.1.3 Middle East Prostate Cancer Medicine Market Status (2016-2021)

9.1.4 Africa Prostate Cancer Medicine Market Status (2016-2021)

9.2 Middle East and Africa Prostate Cancer Medicine Market Status by Manufacturers

9.3 Middle East and Africa Prostate Cancer Medicine Market Status by Type

(2016-2021)

9.3.1 Middle East and Africa Prostate Cancer Medicine Sales by Type (2016-2021)

9.3.2 Middle East and Africa Prostate Cancer Medicine Revenue by Type (2016-2021)

9.4 Middle East and Africa Prostate Cancer Medicine Market Status by Downstream Industry (2016-2021)

CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF PROSTATE CANCER MEDICINE

10.1 Global Economy Situation and Trend Overview

10.2 Prostate Cancer Medicine Downstream Industry Situation and Trend Overview

CHAPTER 11 PROSTATE CANCER MEDICINE MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS

11.1 Production Volume of Prostate Cancer Medicine by Major Manufacturers

11.2 Production Value of Prostate Cancer Medicine by Major Manufacturers

11.3 Basic Information of Prostate Cancer Medicine by Major Manufacturers

11.3.1 Headquarters Location and Established Time of Prostate Cancer Medicine

Major Manufacturer

11.3.2 Employees and Revenue Level of Prostate Cancer Medicine Major

Manufacturer

11.4 Market Competition News and Trend

11.4.1 Merger, Consolidation or Acquisition News

11.4.2 Investment or Disinvestment News

11.4.3 New Product Development and Launch

CHAPTER 12 PROSTATE CANCER MEDICINE MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA

12.1 AstraZeneca plc

12.1.1 Company profile

- 12.1.2 Representative Prostate Cancer Medicine Product
- 12.1.3 Prostate Cancer Medicine Sales, Revenue, Price and Gross Margin of AstraZeneca plc
- 12.2 Active Biotech
 - 12.2.1 Company profile
 - 12.2.2 Representative Prostate Cancer Medicine Product
 - 12.2.3 Prostate Cancer Medicine Sales, Revenue, Price and Gross Margin of Active Biotech
- 12.3 Bristol Myers-Squibb
 - 12.3.1 Company profile
 - 12.3.2 Representative Prostate Cancer Medicine Product
 - 12.3.3 Prostate Cancer Medicine Sales, Revenue, Price and Gross Margin of Bristol Myers-Squibb
- 12.4 Teva Pharmaceuticals Industries Ltd.
 - 12.4.1 Company profile
 - 12.4.2 Representative Prostate Cancer Medicine Product
 - 12.4.3 Prostate Cancer Medicine Sales, Revenue, Price and Gross Margin of Teva Pharmaceuticals Industries Ltd.
- 12.5 Johnson & Johnson
 - 12.5.1 Company profile
 - 12.5.2 Representative Prostate Cancer Medicine Product
 - 12.5.3 Prostate Cancer Medicine Sales, Revenue, Price and Gross Margin of Johnson & Johnson
- 12.6 Pfizer Inc.
 - 12.6.1 Company profile
 - 12.6.2 Representative Prostate Cancer Medicine Product
 - 12.6.3 Prostate Cancer Medicine Sales, Revenue, Price and Gross Margin of Pfizer Inc.
- 12.7 Bayer AG
 - 12.7.1 Company profile
 - 12.7.2 Representative Prostate Cancer Medicine Product
 - 12.7.3 Prostate Cancer Medicine Sales, Revenue, Price and Gross Margin of Bayer AG
- 12.8 Abbott Laboratories
 - 12.8.1 Company profile
 - 12.8.2 Representative Prostate Cancer Medicine Product
 - 12.8.3 Prostate Cancer Medicine Sales, Revenue, Price and Gross Margin of Abbott Laboratories
- 12.9 Astellas Pharma Inc.

- 12.9.1 Company profile
- 12.9.2 Representative Prostate Cancer Medicine Product
- 12.9.3 Prostate Cancer Medicine Sales, Revenue, Price and Gross Margin of Astellas Pharma Inc.
- 12.10 Roche Holding AG
 - 12.10.1 Company profile
 - 12.10.2 Representative Prostate Cancer Medicine Product
 - 12.10.3 Prostate Cancer Medicine Sales, Revenue, Price and Gross Margin of Roche Holding AG

CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF PROSTATE CANCER MEDICINE

- 13.1 Industry Chain of Prostate Cancer Medicine
- 13.2 Upstream Market and Representative Companies Analysis
- 13.3 Downstream Market and Representative Companies Analysis

CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF PROSTATE CANCER MEDICINE

- 14.1 Cost Structure Analysis of Prostate Cancer Medicine
- 14.2 Raw Materials Cost Analysis of Prostate Cancer Medicine
- 14.3 Labor Cost Analysis of Prostate Cancer Medicine
- 14.4 Manufacturing Expenses Analysis of Prostate Cancer Medicine

CHAPTER 15 REPORT CONCLUSION

CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE

- 16.1 Methodology/Research Approach
 - 16.1.1 Research Programs/Design
 - 16.1.2 Market Size Estimation
 - 16.1.3 Market Breakdown and Data Triangulation
- 16.2 Data Source
 - 16.2.1 Secondary Sources
 - 16.2.2 Primary Sources
- 16.3 Reference

I would like to order

Product name: Prostate Cancer Medicine-Global Market Status & Trend Report 2016-2026 Top 20 Countries Data

Product link: <https://marketpublishers.com/r/P6ED95439033EN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P6ED95439033EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

